CAR T and Bispecific Agents in Hematologic Malignancies

Emerging perspectives on the current and potential roles of bispecific agents and CAR T in myeloma, leukemia, and lymphomas: application, investigational approaches, and management of toxicities

September 8, 2020


Elias Jabbour, MD

The University of Texas MD Anderson Cancer Center Houston, TX, USA

Faculty Members

Justin Kline, MD
Jae Park, MD
Sattva Neelapu, MD
Daniel DeAngelo, MD, PhD
Stephen Schuster, MD
Timothy Fenske, MD, MS
Joshua Brody, MD
Nina Shah, MD
Julio Chavez, MD
Michel Sadelain, MD, PhD
Krina K. Patel, MD

Sample Report

Start discovering the insights

View Report


  • The Nature of Bispecific Agents and Application in Leukemias
  • Investigational Approaches for Bispecific Agents
  • CAR T in DLBCL, MCL and FL, ALL, and MM
  • Managing Toxicities of Bispecifics and CAR T Cells

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.